Physician profile
Robert B Marlow
NPI 1487738894
$8,343.35
in general payments reported to CMS, 2019-2025
39 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $1,173 · 2021: $821 · 2022: $948 · 2023: $1,823 · 2024: $1,307 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,460 · Entertainment: $13.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,459.95 |
| Entertainment | $13.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,634.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,053.37 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $1,010.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $800.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $737.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $442.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $317.13 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $307.50 | 2019-2022 | |
| Amgen INC. | $196.06 | 2019-2025 | Repatha, Otezla |
| Abbott Laboratories | $178.76 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $148.50 | 2020-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $148.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corium, LLC | $121.96 | 2023 | Azstarys |
| Dynavax Technologies Corporation | $120.45 | 2023-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $119.51 | 2024-2025 | Voquezna |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Marlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.